Pharma Rep Focus

Bayer needs 'midsize acquisition' to reach $10B oncology sales goal, exec says

Fierce Pharma

JUNE 12, 2023

Bayer recently laid out its ambition | Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.

Sales goal

Sales goal Sales

JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC deals

Fierce Pharma

JANUARY 9, 2024

San Francisco—Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates | Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates, Pfizer’s newly minted chief oncology officer Chris Boshoff, Ph.D.,

4 Ways to Bring Greater Precision to Oncology Omnichannel Experiences

Fierce Pharma

FEBRUARY 1, 2024

Cultivating Connections: Continuity in Patient Engagement | 4 Ways to Bring Greater Precision to Oncology Omnichannel Experiences

Patients

Oncology DTC: Opportunities

World of DTC Marketing

SEPTEMBER 18, 2020

IN SUMMARY: According to a Takeda Oncology report “for people diagnosed with multiple myeloma, there can be an abundance of information, which can lead to confusion around the next steps in their diagnosis and treatment plan. Oncology DTC needs to distinguish the key benefits of products in terms that patients will understand.

Physicians

Physicians Patients Engineering Doctors

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight.

FDA

Coherus sells Lucentis biosim to Sandoz for $170M to focus on oncology

Fierce Pharma

JANUARY 22, 2024

But the Redwood City, California, drugmaker has sold it off to Sandoz for $170 million to focus its efforts on oncology, Coherus said on Monday. . | Lucentis biosimilar Cimerli is the best-selling product for Coherus BioSciences, accounting for 54% of its revenue in the third quarter of last year.

Teva enters into oncology biosimilar licensing agreement

European Pharmaceutical Review

APRIL 16, 2024

A new global licensing agreement is set to advance development of an oncology biosimilar candidate. and Spain-based biopharmaceutical company mAbxience, have entered into a strategic deal for a drug candidate that is in development for treating multiple indications in the oncology space.

Healthcare

Healthcare Healthcare Manufacturing Marketing

FDA's oncology office uses advisory committee to spotlight timely accelerated approval confirmation

Fierce Pharma

NOVEMBER 14, 2023

An upcoming meeting of the FDA’s oncologic drugs advisory committee is slated to serve as a reminder for cancer drug developers that the agency is keeping a close eye on accelerated approvals. |

FDA

Gilead, looking to grow in oncology, posts big gains for its cell therapies and Trodelvy

Fierce Pharma

APRIL 28, 2023

Gilead, looking to grow in oncology, posts big gains for its cell therapies and Trodelvy zbecker Fri, 04/28/2023 - 08:15

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

MARCH 15, 2024

The field of oncology is rapidly growing and evolving. Specific challenges facing the oncology field 1. There are currently more than 2,000 oncology products under development. In addition, access to oncology medicines remains unequal across different countries (7). However, with rapid growth comes growing pains.

Recruitment

Recruitment Healthcare Provider Patients Healthcare

There’s No Place Like Home When It Comes to Oncology Care and Clinical Trials

Fierce Pharma

APRIL 19, 2023

There’s No Place Like Home When It Comes to Oncology Care and Clinical Trials mteefey Wed, 04/19/2023 - 13:40

Bayer’s oncology business looks to collect $10B in sales by 2030, exec says

Fierce Pharma

JANUARY 24, 2023

Bayer’s oncology business looks to collect $10B in sales by 2030, exec says zbecker Tue, 01/24/2023 - 09:14

Sales

Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo

Fierce Pharma

JANUARY 24, 2023

Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo fkansteiner Tue, 01/24/2023 - 16:13

CG Oncology is first biotech IPO of 2024, raising $380m

pharmaphorum

JANUARY 24, 2024

CG Oncology completes the first biotech IPO of 2024, raising $380 million for its oncolytic virus bladder cancer immunotherapy.

At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy

MedCity News

JANUARY 9, 2024

Though GSK divested much of its oncology assets to Novartis in 2015, the company has built it back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P.

Healthcare

Healthcare Healthcare Biopharma Pharma

GLP-1 surge, oncology stars to power industry's earnings growth over the next 18 months: Moody's

Fierce Pharma

MARCH 14, 2024

Besides GLP-1 medicines, the analysts see oncology blockbusters and immunology drugs continuing to gain steam.

Medicine

Gilead, building out its oncology group, expects $3B from Trodelvy, Tecartus and Yescarta this year

Fierce Pharma

AUGUST 4, 2023

For years, Gilead has been on a mission to become a power player in oncology. | The company is sticking to its ambitions of pulling a third of its revenue from its oncology portfolio by 2030. This year, the company expects $3 billion to come from its cancer trio of Trodelvy, Tecartus and Yescarta.

GSK immuno-oncology treatment achieves novel EU approval

European Pharmaceutical Review

DECEMBER 11, 2023

The European Commission (EC) has approved the first frontline immuno-oncology treatment in the EU for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The post GSK immuno-oncology treatment achieves novel EU approval appeared first on European Pharmaceutical Review.

Patients

Patients Medicine Medical Pharmaceutical

'The Top Line': Panelists at Fierce's JPM Week event talk drug pricing policy, and Bayer's oncology head discusses cancer strategy

Fierce Pharma

JANUARY 19, 2023

The Top Line': Panelists at Fierce's JPM Week event talk drug pricing policy, and Bayer's oncology head discusses cancer strategy qanderson Thu, 01/19/2023 - 11:05

Collaboration to develop novel AI-designed oncology therapy

European Pharmaceutical Review

JANUARY 5, 2024

This treatment has potential for hormone sensitive cancers such as breast cancer, and other oncology indications. The post Collaboration to develop novel AI-designed oncology therapy appeared first on European Pharmaceutical Review. Under a new licensing agreement, Stemline Therapeutics, Inc.,

Medicine

Medicine Biopharma Patients Pharmaceutical

Bladder cancer-focused CG Oncology files for IPO

Pharmaceutical Technology

JANUARY 22, 2024

On 18 January 2024, US-based biotech CG Oncology announced it was looking to raise $200m in an upcoming initial public offering (IPO), which will be the first for the biotech sector in 2024.

AbbVie agrees $10 billion oncology acquisition

European Pharmaceutical Review

DECEMBER 1, 2023

Richard Gonzalez, Chairman and Chief Executive Officer for AbbVie stated that the acquisition of ImmunoGen enables the company to further diversify its oncology pipeline across solid tumours and haematologic malignancies. The post AbbVie agrees $10 billion oncology acquisition appeared first on European Pharmaceutical Review.

Food and Drug Administration

Food and Drug Administration FDA Marketing Food

Merck, Johnson & Johnson Announce Acquisitions to Bolster Respective Oncology Pipelines

PharmExec

JANUARY 9, 2024

Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its expertise in next generation antibody drug conjugates and targeted oncologic therapies.

Biopharma

Labcorp Announces Expansions to Oncology Portfolio

PharmExec

APRIL 9, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Antibody-drug conjugates: paving the future of oncology clinical development

European Pharmaceutical Review

OCTOBER 26, 2023

Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months. What are the current trends in clinical development for oncology?

Patients

Patients Pharmaceutical Safety Marketing

Advancing Healthcare Solutions: Harnessing Collaborative Business Models for Oncology

PharmExec

APRIL 18, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Healthcare

Healthcare Healthcare

Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline

Fierce Pharma

DECEMBER 14, 2023

Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal. Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019.

Biopharma

Generate:Biomedicines to collaborate on oncology cell therapies

Pharmaceutical Technology

NOVEMBER 2, 2023

Generate:Biomedicines has entered a strategic collaboration with Roswell Park to accelerate the development of new oncology therapies

CG Oncology lines up $180m IPO and a $1bn valuation

pharmaphorum

JANUARY 19, 2024

CG Oncology joins the queue of US biotech companies hoping to complete an IPO, aiming to raise $181m for its late-stage bladder cancer therapy.

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

SEPTEMBER 1, 2023

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. Global mRNA-based oncology therapy market At present, the pharmaceutical industry is still awaiting the first regulatory approval of an mRNA-based oncology therapy. percent share by 2029, the research has shown.

Marketing

Marketing Sales Competition Pharmaceutical

AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod

Fierce Pharma

APRIL 8, 2024

With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s (ADC's) reach in the U.S.<

FDA

Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition

MedCity News

APRIL 27, 2023

Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.

Patients

Patients Biopharma

Clovis Oncology finally throws in the towel, files for bankruptcy

Fierce Pharma

DECEMBER 12, 2022

Clovis Oncology finally throws in the towel, files for bankruptcy. Mon, 12/12/2022 - 11:34.

The other COVID-19 health crisis in Oncology

World of DTC Marketing

FEBRUARY 11, 2021

Pharma, who seems to be promoting a number of oncology drugs, has remained silent. At a minimum, they should be announcing on their oncology drug websites the importance of continuing treatment without delay. The post The other COVID-19 health crisis in Oncology appeared first on World of DTC Marketing.com.

Insurance

Insurance Healthcare Healthcare Pharma

Avenzo Therapeutics secures $150m to progress oncology pipeline

Pharmaceutical Technology

MARCH 27, 2024

Avenzo Therapeutics has secured $150m in Series A-1 financing round to progress the development of its oncology pipeline.

Bayer pledges up to $1.5bn for Recursion oncology alliance

pharmaphorum

NOVEMBER 10, 2023

Bayer pledges up to $1.5bn for Recursion oncology alliance Phil.Taylor Fri, 10/11/2023 - 11:19 Bookmark this

ADC oncology therapy market to value over $36b by 2029

European Pharmaceutical Review

AUGUST 9, 2023

According to research from GlobalData, the pharmaceutical industry is shifting towards development of antibody-drug conjugates (ADC) as oncology treatments. Future of the antibody-drug conjugate therapy market By 2029, the global market for ADC therapies in oncology is expected to be worth more than $36 billion, the research predicted.

Marketing

Marketing Pharmaceutical Manufacturing

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

pharmaphorum

NOVEMBER 14, 2023

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial Phil.Taylor Tue, 14/11/2023 - 09:52 Bookmark this

FDA advisers back new endpoint for myeloma approvals, paving way for faster introduction of new drugs

Fierce Pharma

APRIL 12, 2024

After oncology experts reviewed arguments in favor of a surrogate endpoint to support multiple myeloma drug approvals, drug developers may soon have a new pathway in the R&D journey.

FDA

Ikena Oncology gets grant for cancer treatment method using compounds of formula i

Pharmaceutical Technology

APRIL 18, 2024

Discover the groundbreaking patent by Ikena Oncology Inc for treating cancer with specific compounds and methods. Learn how this innovative approach targets cancers with increased TEAD expression, offering hope for effective treatment.

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

MAY 4, 2023

Martin Vogel, Janssen’s Therapeutic Area Lead Oncology for the Europe, Middle-East and Africa (EMEA) region shared with EPR what makes the BsMAb promising for treating this indication. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Cancer Ther. 2020; 19(10): 2044–56. Finn OJ, et al.

Food and Drug Administration

Food and Drug Administration Safety Medicine Patients

GSK acquires US-based Sierra Oncology for $1.9bn

Pharmaceutical Technology

JULY 4, 2022

GlaxoSmithKline (GSK) has completed the acquisition of all outstanding shares of US-based Sierra Oncology in a deal totalling $1.9bn (£1.6bn), in cash. In April this year, GSK entered an agreement for the acquisition of Sierra Oncology for $55 per share. Sierra develops targeted treatments for rare kinds of cancer.

Food and Drug Administration

Food and Drug Administration Food Medicine Patients

US FDA approves Shorla’s oncology drug for T-cell leukaemia

Pharmaceutical Technology

MARCH 8, 2023

The US Food and Drug Administration (FDA) has granted approval for Shorla Oncology’s Nelarabine Injection, an oncology drug, to treat T-cell leukaemia, an aggressive blood and bone marrow cancer that progresses quickly. The company develops innovative oncology drugs with a focus on paediatric and orphan cancers.

Food and Drug Administration

Food and Drug Administration FDA Food Patients

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies.

Marketing

Marketing Physicians Insurance Pharmaceutical

Bayer needs 'midsize acquisition' to reach $10B oncology sales goal, exec says

JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC deals

Trending Sources

4 Ways to Bring Greater Precision to Oncology Omnichannel Experiences

Oncology DTC: Opportunities

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Coherus sells Lucentis biosim to Sandoz for $170M to focus on oncology

Teva enters into oncology biosimilar licensing agreement

FDA's oncology office uses advisory committee to spotlight timely accelerated approval confirmation

Gilead, looking to grow in oncology, posts big gains for its cell therapies and Trodelvy

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

There’s No Place Like Home When It Comes to Oncology Care and Clinical Trials

Bayer’s oncology business looks to collect $10B in sales by 2030, exec says

Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo

CG Oncology is first biotech IPO of 2024, raising $380m

At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy

GLP-1 surge, oncology stars to power industry's earnings growth over the next 18 months: Moody's

Gilead, building out its oncology group, expects $3B from Trodelvy, Tecartus and Yescarta this year

GSK immuno-oncology treatment achieves novel EU approval

'The Top Line': Panelists at Fierce's JPM Week event talk drug pricing policy, and Bayer's oncology head discusses cancer strategy

Collaboration to develop novel AI-designed oncology therapy

Bladder cancer-focused CG Oncology files for IPO

AbbVie agrees $10 billion oncology acquisition

Merck, Johnson & Johnson Announce Acquisitions to Bolster Respective Oncology Pipelines

Labcorp Announces Expansions to Oncology Portfolio

Antibody-drug conjugates: paving the future of oncology clinical development

Advancing Healthcare Solutions: Harnessing Collaborative Business Models for Oncology

Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline

Generate:Biomedicines to collaborate on oncology cell therapies

CG Oncology lines up $180m IPO and a $1bn valuation

$2 billion mRNA-based oncology therapy market anticipated by 2029

AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod

Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition

Clovis Oncology finally throws in the towel, files for bankruptcy

The other COVID-19 health crisis in Oncology

Avenzo Therapeutics secures $150m to progress oncology pipeline

Bayer pledges up to $1.5bn for Recursion oncology alliance

ADC oncology therapy market to value over $36b by 2029

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

FDA advisers back new endpoint for myeloma approvals, paving way for faster introduction of new drugs

Ikena Oncology gets grant for cancer treatment method using compounds of formula i

Transforming oncology with antibody therapeutics

GSK acquires US-based Sierra Oncology for $1.9bn

US FDA approves Shorla’s oncology drug for T-cell leukaemia

Immuno-oncology market set to grow in billions, but access concerns remain

Stay Connected